Oral antiplatelet therapy – half a century of evolution
It is now 50 years since the first randomised, controlled trial of aspirin in the secondary prevention of mortality from myocardial infarction (MI)[1]. Although the results of the trial were statistically inconclusive, positive signals were observed. Over the next two decades, multiple studies were conducted in a range of patient groups leading to the conclusion […]
